Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23272901 | 0.82 | MAPK14 (0.31) | — | |
| SCHEMBL29823297 | 0.82 | MAPK14 (0.31) | — | |
| SCHEMBL23899523 | 0.82 | KDM4E (0.33) | PLAUACLY | |
| SCHEMBL25204018 | 0.80 | ERN1 (0.38) | — | |
| SCHEMBL29276192 | 0.79 | PLAU (0.31) | PLAU | |
| SCHEMBL30994961 | 0.79 | PLAU (0.31) | PLAU | |
| SCHEMBL5769814 | 0.75 | S1PR4 (0.45) | — | |
| SCHEMBL23899524 | 0.74 | EGFR (0.35) | — | |
| SCHEMBL23883881 | 0.74 | KDM4E (0.33) | PLAUACLY | |
| SCHEMBL30335376 | 0.74 | KDM4E (0.33) | PLAUACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042879-A1 | HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| CN-118843625-A | Heterocyclically substituted 1,3, 4-thiadiazole and pyridazine compounds and methods of use thereof | 亚根达医疗公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-4436665-A1 | HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME | Rgenta Therapeutics, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2023092149-A1 | HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042879-A1 | HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME | RBM17, SF3B5, SF3A2 | PLAU 2361/4885ACLY 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.